(-1.11%) 5 059.45 points
(-1.21%) 37 920 points
(-1.32%) 15 772 points
(-1.17%) $81.66
(-2.46%) $1.980
(-2.35%) $2 302.40
(-3.76%) $26.62
(-1.54%) $946.70
(0.48%) $0.937
(1.02%) $11.09
(0.54%) $0.800
(0.20%) $93.49
Live Chart Being Loaded With Signals
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant...
Stats | |
---|---|
今日成交量 | 10.25M |
平均成交量 | 9.29M |
市值 | 2 714.75B |
EPS | ¥0 ( 2024-04-25 ) |
Last Dividend | ¥30.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 558.67 |
ATR14 | ¥0.662 (0.04%) |
音量 相关性
Astellas Pharma Inc. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Astellas Pharma Inc. 相关性 - 货币/商品
Astellas Pharma Inc. 财务报表
Annual | 2023 |
营收: | ¥1 603.67B |
毛利润: | ¥1 212.37B (75.60 %) |
EPS: | ¥9.50 |
FY | 2023 |
营收: | ¥1 603.67B |
毛利润: | ¥1 212.37B (75.60 %) |
EPS: | ¥9.50 |
FY | 2022 |
营收: | ¥1 518.62B |
毛利润: | ¥1 230.27B (81.01 %) |
EPS: | ¥54.24 |
FY | 2022 |
营收: | ¥1 296.16B |
毛利润: | ¥1 043.15B (80.48 %) |
EPS: | ¥67.08 |
Financial Reports:
No articles found.
Astellas Pharma Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥30.00 (N/A) |
¥0 (N/A) |
¥30.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥3.00 | 2000-03-28 |
Last Dividend | ¥30.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 48 | -- |
Total Paid Out | ¥591.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.71 | -- |
Div. Sustainability Score | 8.06 | |
Div.Growth Potential Score | 6.81 | |
Div. Directional Score | 7.43 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8168.T | Ex Dividend Junior | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
7545.T | Ex Dividend Knight | 2024-02-19 | Semi-Annually | 0 | 0.00% | |
6755.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6098.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4801.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
4023.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3232.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
2264.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
9757.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
8818.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00805 | 1.500 | 9.84 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00362 | 1.200 | 9.88 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.00817 | 1.500 | -1.020 | -1.530 | [0.1 - 1] |
payoutRatioTTM | 9.04 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 0.929 | 0.800 | -0.354 | -0.283 | [1 - 3] |
quickRatioTTM | 0.687 | 0.800 | -0.663 | -0.530 | [0.8 - 2.5] |
cashRatioTTM | 0.261 | 1.500 | 9.66 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.258 | -1.500 | 5.70 | -8.56 | [0 - 0.6] |
interestCoverageTTM | 8.97 | 1.000 | 7.79 | 7.79 | [3 - 30] |
operatingCashFlowPerShareTTM | 97.61 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 51.61 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.576 | -1.500 | 7.69 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.797 | 1.000 | 0.0457 | 0.0457 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0672 | 1.000 | -0.657 | -0.657 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.190 | 1.000 | -0.0541 | -0.0541 | [0.2 - 2] |
assetTurnoverTTM | 0.449 | 0.800 | -0.338 | -0.271 | [0.5 - 2] |
Total Score | 8.06 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 210.39 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.00817 | 2.50 | -0.656 | -1.530 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 51.61 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.62 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 97.61 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 9.04 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 63.54 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.109 | 1.000 | 9.77 | 0 | [0.1 - 0.5] |
Total Score | 6.81 |
Astellas Pharma Inc.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。